Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Amgen Inc. is conducting a study titled ‘A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study.’ The study aims to evaluate the safety and tolerability of sotorasib, alone or in combination with panitumumab, in patients with advanced solid tumors who have previously benefited from Amgen-sponsored protocols. This study is significant as it explores continued treatment options for patients with specific genetic mutations in cancer.
Intervention/Treatment: The study tests two interventions: sotorasib, an oral drug administered daily, and a combination of sotorasib with panitumumab, an IV infusion given bi-weekly. These treatments aim to provide continued therapeutic benefits to patients with the KRAS p.G12C mutation.
Study Design: The study is interventional, non-randomized, and follows a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused. Participants will receive treatment for up to 18 months or until certain conditions such as withdrawal or death occur.
Study Timeline: The study is not yet recruiting, with a start date submitted on September 8, 2025. This date marks the beginning of participant recruitment and data collection. The primary completion and estimated completion dates are yet to be announced, indicating ongoing planning and preparation stages.
Market Implications: This study update could positively impact Amgen’s stock performance by showcasing ongoing innovation and commitment to targeted cancer therapies. The focus on the KRAS p.G12C mutation, a challenging target in oncology, positions Amgen competitively in the industry. Investors may view this as a strategic move to strengthen Amgen’s oncology portfolio amidst growing competition.
The study is ongoing, with further details available on the ClinicalTrials portal.